Novartis Shares Sink as Pipeline Setbacks Compound in Brutal Week for Drug Developer

Novartis stock drops 11% after Del-Desiran fails key trial, following Pelacarsen miss, erasing CHF 24B in market value.

The Swiss pharmaceutical giant is nursing its heaviest one-day share decline in years, with investors punishing the stock after a second major clinical failure in the span of a week cast a shadow over the company's growth ambitions.

Novartis shares tumbled roughly 11 percent to €119.28 in Tuesday trading, erasing approximately CHF 24 billion in market value. The sell-off ranks among the steepest single-day drops in the company's modern history, eclipsing even the turmoil witnessed during the 2020 coronavirus crash and the fallout from the Swiss National Bank's decision to abandon its euro currency floor in 2015.

Lead Drug Candidate Misses Primary Goal in Rare Disease Trial

At the heart of Tuesday's rout is Del-Desiran, the experimental therapy that formed the centerpiece of Novartis' roughly $12 billion acquisition of biotech firm Avidity. In the pivotal Harbor study, the drug candidate failed to demonstrate a statistically significant improvement in hand-opening time (vHOT) compared with placebo among approximately 150 patients with myotonic dystrophy type 1, a rare and debilitating muscle disorder, over a 54-week treatment period.

While Novartis pointed to secondary endpoints that suggested clinical activity and hints of efficacy, the miss on the primary objective weighed heavily on investor sentiment. Management has pledged to conduct a detailed analysis of the data and consult with health authorities on next steps.

The setback marks the third research disappointment for Novartis within a single week, raising fresh questions about the near-term strength of its drug pipeline. Just a day earlier, the company disclosed that Pelacarsen, developed to lower cardiovascular risk, had also failed to meet its goals in a large-scale study. That news, confirmed Friday alongside partner Ionis Pharmaceuticals, showed the drug effectively reduced lipoprotein(a) levels in the blood — yet this biochemical effect did not translate into the anticipated reduction in major cardiovascular events such as heart attacks and strokes.

Analysts Scramble to Reset Expectations

The research community moved quickly to recalibrate its outlook. Vontobel analysts stripped out the entire projected peak sales potential for Del-Desiran — previously estimated at $3 billion — from their models, cutting their price target to CHF 125 in the process. Jefferies maintained its "Hold" rating with a CHF 110 target, while flagging concerns about the due diligence conducted ahead of the Avidity acquisition. The Zürcher Kantonalbank characterized the failure as a significant erosion of confidence in the underlying technology platform.

The stock now trades roughly 12 percent below its 50-day moving average, a technical signal that underscores the severity of the recent decline. The setback also deepens the discount to the 52-week high, with the shares now sitting about 15 percent off those levels.

Broader Pipeline Pressures Mount

The clinical disappointments arrive amid a period of heightened scrutiny for Novartis' research operations. Earlier this week, the company announced a pause in its experimental "rap-cel" cell therapy program, halting eight clinical studies in autoimmune diseases and neurology following three patient deaths linked to severe immunological reactions. Oncology studies under the program remain unaffected.

On a more positive note, Novartis reported success on September 1 with Remibrutinib, which hit its primary goals in two late-stage trials for relapsing multiple sclerosis. The company plans to file for regulatory approvals worldwide and will present full results in October.

The same day brought news of a licensing agreement with Alteogen worth up to $3.22 billion, securing access to the Hybrozyme technology that converts intravenously administered drugs into simpler injectable versions.

Management Strikes a Defiant Tone

Chief Medical Officer Shreeram Aradhye sought to frame the recent failures as an inherent part of scientific progress, though the message did little to soothe investor nerves. The company reaffirmed its financial guidance for 2025 through 2030, maintaining expectations for annual sales growth of 5 to 6 percent.

Attention now shifts to other pipeline assets, notably Del-Zota for Duchenne muscular dystrophy, which has already received accelerated review status from regulators. Whether such programs can fill the void left by these latest disappointments remains an open question — one that will likely define the stock's trajectory in the coming months.

Operationally, Novartis is also streamlining its Basel/Kleinbasel footprint, with media reports suggesting around 130 positions could be cut as biologics production capacity and laboratories are consolidated into the company's existing European manufacturing network.